Article Text

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Free
  1. Nicole Concin1,2,
  2. Xavier Matias-Guiu3,4,
  3. Ignace Vergote5,
  4. David Cibula6,
  5. Mansoor Raza Mirza7,
  6. Simone Marnitz8,
  7. Jonathan Ledermann9,
  8. Tjalling Bosse10,
  9. Cyrus Chargari11,
  10. Anna Fagotti12,
  11. Christina Fotopoulou13,
  12. Antonio Gonzalez Martin14,
  13. Sigurd Lax15,16,
  14. Domenica Lorusso12,
  15. Christian Marth17,
  16. Philippe Morice18,
  17. Remi A Nout19,
  18. Dearbhaile O'Donnell20,
  19. Denis Querleu12,21,
  20. Maria Rosaria Raspollini22,
  21. Jalid Sehouli23,
  22. Alina Sturdza24,
  23. Alexandra Taylor25,
  24. Anneke Westermann26,
  25. Pauline Wimberger27,
  26. Nicoletta Colombo28,
  27. François Planchamp29 and
  28. Carien L Creutzberg30
  1. 1 Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria
  2. 2 Evangelische Kliniken Essen-Mitte, Essen, Germany
  3. 3 Department of Pathology, Hospital Universitari Arnau de Vilanova, University of Lleida, CIBERONC, Irblleida, Spain
  4. 4 Department of Pathology, Hospital Universitari de Bellvitge, University of Barcelona, Idibell, Spain
  5. 5 Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
  6. 6 Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic
  7. 7 Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
  8. 8 Department of Radiation Oncology, Medical Faculty of the University of Cologne, Cologne, Germany
  9. 9 UCL Cancer Institute, University College, London, UK
  10. 10 Department of Pathology, Leids Universitair Medisch Centrum, Leiden, Netherlands
  11. 11 Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
  12. 12 Division of Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
  13. 13 Department of Gynaecologic Oncology, Imperial College London Faculty of Medicine, London, UK
  14. 14 Department of Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain
  15. 15 Department of Pathology, Hospital Graz II, Graz, Austria
  16. 16 School of Medicine, Johannes Kepler University Linz, Linz, Austria
  17. 17 Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
  18. 18 Department of Surgery, Institut Gustave Roussy, Villejuif, France
  19. 19 Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands
  20. 20 Department of Medical Oncology, St James Hospital, Dublin, Ireland
  21. 21 Department of Obstetrics and Gynecologic Oncology, University Hospital, Strasbourg, France
  22. 22 Histopathology and Molecular Diagnostics, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
  23. 23 Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany
  24. 24 Department of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria
  25. 25 Department of Gynaecology, Royal Marsden Hospital, London, UK
  26. 26 Department of Medical Oncology, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, Netherlands
  27. 27 Department of Gynecology and Obstetrics, TU Dresden Medizinische Fakultat Carl Gustav Carus, Dresden, Germany
  28. 28 Gynecologic Oncology Program, European Institute of Oncology, IRCCS, Milan and University of Milan-Bicocca, Milan, Italy
  29. 29 Clinical Research Unit, Institut Bergonie, Bordeaux, France
  30. 30 Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands
  1. Correspondence to Nicole Concin, Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck 6020, Austria; nicole.concin{at}i-med.ac.at

Abstract

A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide.

  • uterine cancer
  • surgery
  • radiation
  • pathology

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Presented at These guidelines statements were developed by ESGO, ESTRO and ESP and are published in the International Journal of Gynaecological Cancer, Radiotherapy & Oncology and the Virchows Archiv.

  • Contributors The development group (including all authors) is collectively responsible for the decision to submit for publication. NCon (chair), CLC (co-chair), XM-G (co-chair) and FP (methodologist) have written the first draft of the manuscript. All other contributors have actively given personal input, reviewed the manuscript, and have given final approval before submission.

  • Funding All costs relating to the development process were covered from ESGO, ESTRO, and ESP funds.

  • Competing interests NCon: advisory boards for Seattle Genetics, AstraZeneca and Mersana, education fees from Medscape Oncology, and grants for travelling from Roche, Genmab and Amgen. IV: advisory boards for Amgen, AstraZeneca, Clovis Oncology, Carrick Therapeutics, Debiopharm International, F Hoffmann-La Roche, Genmab, GSK, Immunogen, Millenium Pharmaceuticals, MSD Belgium, Octimet Oncology, Oncoinvent, Pharmamar-Doctaforum Servicios, Roche, Sotio, Tesaro, Deciphera Pharmaceuticals and Verastem Oncology (fees for consulting to his university), contracted research (KU Leuven) for Oncoinvent AS and Genmab, corporate sponsored research for Amgen and Roche, and grants for travelling from Amgen, MSD/Merck, Roche, AstraZeneca and Tesaro. DC: advisory boards for AstraZeneca, Roche, Sotio and Novocure. MRM: personal financial interests for AstraZeneca, Biocard, Clovis Oncology, Geneos, Genmab, Karyopharm Therapeutics, Merck, Mersana, MSD, Oncology Venture, Pfizer, Roche, SeatleGenetics, SeraPrognostics, Sotio, Tesaro-GSK, ZaiLab; leadership role for Karyopharm Therapeutics, Sera Prognostics; institutional financial interests (study grants) for AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Pfizer, Tesaro-GSK, Ultimovacs. JL: advisory boards for AstraZeneca, Pfizer, GSK, Eisai, MSD/Merck, Artios Pharma, Regeneron, Amgen and Clovis Oncology, and grants for travelling from Clovis Oncology. CC: advisory boards for MSD, Takeda and GSK, conducting research for TherAguiX and Roche, and grants for travelling from Takeda. AF: advisory boards for GSK and Johnson & Johnson SpA, and grants for travelling from Pharmmar and MSD Italia. CF: advisory boards for AstraZeneca, Clovis, Ethicon, Roche, MSD, GSK and Tesaro, and grants for travelling from Sequana. AGM: speakers’ bureau activities for AstraZeneca, Pharmamar, Roche and GSK, advisory boards for Amgen, AstraZeneca, Clovis Oncology, Genmab, GSK, Immunogen, Merck Sharp & Dohme, Novartis, Oncoinvent, Pfizer/Merck, Pharmamar, Roche and Sotio, and grants for travelling from AstraZeneca, Pharmamar Roche and Tesaro. DL: advisory boards for Roche, Amgen, MSD, GSK, Clovis, AstraZeneca, Immunogen, Genmab, Pharmamar and Merck, and grants for travelling from Pharmamar, GSK, Roche and AstraZeneca. CM: consulting/advisory boards for Roche, Novartis, Amgen, MSD, AstraZeneca, Pfizer, Pharmamar, Cerulean, Vertex and Tesaro, funded research from EU, FWF, AstraZeneca and Roche, and honoraria/expenses from Roche, Novartis, Amgen, MSD, Pharmamar, AstraZeneca and Tesaro. JS: advisory boards for Roche, Eisei, MSD, AstraZeneca, Clovis, GSK and Tesaro. AT: advisory boards for Genmab; PW: advisory boards for Amgen, AstraZeneca, MSD, Novartis, Pfizer, Pharmamar, Lilly, Roche Pharma GmbH, TEVA, Eisai, Clovis and Tesaro, and grants for travelling from Roche Pharma GmbH, AstraZeneca, MSD, Amgen and Pfizer. NC: consulting and advisory services, speaking or writing engagements, public presentations for Roche, AstraZeneca, MSD, Pharmamar, Tesaro, GSK, Clovis, Advaxis, Pfizer, Takeda, Immunogen, Biocad, Amgen, Novartis and Ellipses, institutional financial interests for Roche, Pharmamar and AstraZeneca, and non-financial interests for ESMO clinical Guidelines (subject editor for gynecological cancer). XMG, SM, TB, SL, PM, RN, DOD, DQ, MRR, AS, AW, FP, and CLC: no conflicts of interest.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.